Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Carbonic acid lithium salt (Li2CO3)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 77Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AMEEREX Issues Complementary Clarification to January 7, 2026
    AMEEREX Issues Complementary Clarification to January 7, 2026

    11 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-11/ameerex-corporation-otc-hiru-issues-complementary-clarification-to-january-7-2026-press-release

    PHARMIWEB
    11 Feb 2026
    Share Share
    Ameerex Signs 551K-Ton LCE Deal With Patagonia Lithium
    Ameerex Signs 551K-Ton LCE Deal With Patagonia Lithium

    07 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-07/ameerex-enters-strategic-partnership-with-patagonia-lithium-asx-pl3-gaining-exposure-to-inferred

    PHARMIWEB
    07 Jan 2026
    Share Share
    Alzamend Neuro Starts Phase II AL001 Trial at Hospital
    Alzamend Neuro Starts Phase II AL001 Trial at Hospital

    13 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/13/3080073/0/en/Alzamend-Neuro-Initiates-First-Phase-II-Clinical-Trial-of-AL001-Lithium-in-Brain-Study-Taking-Place-at-Massachusetts-General-Hospital.html

    GLOBENEWSWIRE
    13 May 2025
    Share Share
    Alzamend Reports Lithium Exposure Study in Alzheimer’s Mice
    Alzamend Reports Lithium Exposure Study in Alzheimer’s Mice

    19 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241119240778/en

    BUSINESSWIRE
    19 Nov 2024
    Share Share
    Sanofi offloads rights to prolonged-release antipsychotic drug
    Sanofi offloads rights to prolonged-release antipsychotic drug

    27 Apr 2022

    // Nick Paul Taylor FIERCEPHARMA

    https://www.fiercepharma.com/pharma/sanofi-offloads-rights-prolonged-release-antipsychotic-drug

    Nick Paul Taylor FIERCEPHARMA
    27 Apr 2022
    Share Share
    Preclinical Alzheimer's biotech Alzamend Neuro files for a $12 million IPO
    Preclinical Alzheimer's biotech Alzamend Neuro files for a $12 million IPO

    11 May 2021

    // RENAISSANCECAPITAL

    https://www.renaissancecapital.com/IPO-Center/News/81644/Preclinical-Alzheimers-biotech-Alzamend-Neuro-files-for-a-$12-million-IPO#:~:text=Alzamend%20Neuro%2C%20a%20preclinical%20biotech,in%20an%20initial%20public%20offering.

    RENAISSANCECAPITAL
    11 May 2021
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.